Antimitotic Agents: all 5,052 studies that test it

Page 5 of 51. Open to participants first (616), then studies with results posted, then the rest; newest registration first within each.

• A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast CancerRecruitingNCT05862064Phase 3
• Colchicine Versus Placebo in Acute Myocarditis PatientsRecruitingNCT05855746Phase 3
• Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ CancerRecruitingNCT05853172Phase 2
• Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.RecruitingNCT05838066Phase 3
• PM534 Administered Intravenously to Patients With Advanced Solid TumorsRecruitingNCT05835609Phase 1
• Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast CancerRecruitingNCT05834582Phase 2
• First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)RecruitingNCT05832827Phase 2
• Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal CancerNot yet recruitingNCT05828381Phase 2
• Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaRecruitingNCT05825066Phase 2
• Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint InhibitorsNot yet recruitingNCT05824494Phase 2
• Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast CancerRecruitingNCT05823623Phase 2
• The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.Not yet recruitingNCT05816694Phase 2
• Study of Comparing of With and Without Sequential Therapy of S-1RecruitingNCT05813015Phase 3
• Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract CancerRecruitingNCT05812430Phase 2
• Dose Attenuated Chemotherapy in Compromised Patients With Lung CancerRecruitingNCT05800587Phase 2
• Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic CancerRecruitingNCT05795920Phase 2
• Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET OverexpressionRecruitingNCT05777278Phase 1/2
• Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic CancerRecruitingNCT05776524Phase 2
• Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene MutationRecruitingNCT05761470Phase 2
• Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck TumorsRecruitingNCT05758389Phase 2
• A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial CancerRecruitingNCT05754853Phase 3
• First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLCRecruitingNCT05745350Phase 2
• Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)RecruitingNCT05733689Phase 1
• Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland CarcinomaRecruitingNCT05727410Phase 2
• Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid TumorsRecruitingNCT05693844Phase 1/2
• A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial CancerRecruitingNCT05691010Early Phase 1
• HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid TumorsRecruitingNCT05681650Phase 1/2
• Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)RecruitingNCT05681260Phase 3
• A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingNCT05675410Phase 3
• Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT05673590Phase 3
• Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast CancerRecruitingNCT05659056Phase 2
• A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung CancerRecruitingNCT05654454Phase 3
• TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid TumorsNot yet recruitingNCT05648994Early Phase 1
• Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line TherapyRecruitingNCT05640830Phase 1/2
• Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell CarcinomaRecruitingNCT05637268Phase 2
• Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian CancerRecruitingNCT05636111Phase 1
• A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft TissueRecruitingNCT05634369Phase 1/2
• Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast CancerRecruitingNCT05633914Phase 2
• Combination of CAR-DC Vaccine and ICIs in Malignant TumorsRecruitingNCT05631886Phase 1
• A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic AdenocarcinomaRecruitingNCT05624918Phase 2
• The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) TrialRecruitingNCT05618353Phase 4
• A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic CancerRecruitingNCT05616494Phase 2
• Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer PatientsRecruitingNCT05596890Phase 2
• Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-PaclitaxelRecruitingNCT05582538Phase 2
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2
• Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)RecruitingNCT05563558Phase 2
• Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic CancerNot yet recruitingNCT05562297Phase 2
• De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNARecruitingNCT05541016Phase 2
• Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed MedulloblastomaRecruitingNCT05535166Phase 2
• Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different GenotypesNot yet recruitingNCT05524974Phase 2
• A Phase I Intravesical PPM Therapy for NMIBCRecruitingNCT05519241Phase 1
• B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021RecruitingNCT05518383Phase 4
• Colchicine Use in Intracranial Atherosclerotic DiseaseRecruitingNCT05503225Phase 2
• Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerRecruitingNCT05501665Phase 1/2
• The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell CarcinomaRecruitingNCT05494190Not applicable
• Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to AtherosclerosisRecruitingNCT05476991Phase 3
• Effect of Colchicine on Coronary Reperfusion in Patients With Acute Coronary SyndromeRecruitingNCT05472337Phase 2
• Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT05449483Phase 2
• Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ CarcinomaRecruitingNCT05439993Phase 1/2
• Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast CancerRecruitingNCT05430399Phase 3
• A Study for the Adjuvant Treatment of Breast CancerRecruitingNCT05420467Phase 4
• A Study for the Neoadjuvant Treatment of Breast CancerRecruitingNCT05420454Phase 4
• Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi SarcomaNot yet recruitingNCT05411237Phase 3
• Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast CancerRecruitingNCT05398861Phase 2
• Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel In Patients With Peritoneal CarcinomatosisRecruitingNCT05395910Phase 1
• Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)RecruitingNCT05384821Phase 1/2
• Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AIRecruitingNCT05381038Phase 1/2
• Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III TrialRecruitingNCT05367206Phase 3
• A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerRecruitingNCT05365581Phase 1
• Low-dose Colchicine Inhibit Abdominal Aortic Aneurysm Growth TrialNot yet recruitingNCT05361772Not applicable
• ATATcH Alternating Treatment Plans for Advanced CancerRecruitingNCT05358548Phase 2
• Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & PertuzumabRecruitingNCT05325632Phase 2
• A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingNCT05319730Phase 1/2
• Phase I/II Study of the Combination of Irinotecan and POF (POFI) and TislelizumabRecruitingNCT05319639Phase 1/2
• Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical TrialNot yet recruitingNCT05316376Phase 2
• Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast CancerRecruitingNCT05296577Phase 2
• Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast CancerNot yet recruitingNCT05291910Phase 4
• Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world StudyNot yet recruitingNCT05287308Not applicable
• Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal MetastasesRecruitingNCT05285358Phase 1
• Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor TherapyRecruitingNCT05283226Phase 2
• Modified CV Regimen in Optic Pathway GliomaRecruitingNCT05278715Phase 2
• Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnPRecruitingNCT05268692Phase 2/3
• Perioperative FLOT vs Adjuvant XELOX for CA StomachRecruitingNCT05264896Phase 3
• RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast CancerRecruitingNCT05256745Phase 1/2
• Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic AdenocarcinomaRecruitingNCT05241249Phase 2
• Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCLNot yet recruitingNCT05238064Phase 1/2
• Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic CancerRecruitingNCT05218889Phase 1/2
• Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02RecruitingNCT05205200Phase 2
• Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder CancerRecruitingNCT05203913Phase 2
• Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.RecruitingNCT05189483Phase 2
• Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell CarcinomaNot yet recruitingNCT05189184Phase 2
• Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast CancerRecruitingNCT05189067Phase 2/3
• SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic CancerNot yet recruitingNCT05185869Phase 2
• A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric CancerRecruitingNCT05184803Phase 2
• Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With CancerRecruitingNCT05183126Phase 4
• Colchicine Use for Primary Prevention of Coronary Artery DiseaseNot yet recruitingNCT05175274Phase 3
• JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal CarcinomaRecruitingNCT05173246Phase 2
• Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal CarcinomaNot yet recruitingNCT05151588Phase 2
• Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCCRecruitingNCT05125055Phase 2/3

← Antimitotic Agents overview